Kailera Therapeutics (KLRA.US), a newcomer in the weight-loss drug sector, began trading on the U.S. stock market on Friday, surging more than 50% at the opening to $24.1 per share, compared with its IPO price of $16. The company has set a record for the largest biotechnology IPO in the U.S. since 2021. Founded in 2024, Kailera is a late-stage clinical biotech firm developing four GLP-1-based weight-loss treatments. These include a once-weekly injectable and a once-daily oral pill, both of which have advanced to late-stage clinical trials.